Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioengineering
arGentis Signs Agreement with LifeCyte to Develop cGMP Facility
October 8th, 2007
arGentis(TM) Pharmaceuticals, LLC announced that it had signed an agreement with LifeCyte Inc., a Memphis-based biopharmaceutical services company, to assist in the design and development of a dedicated current Good Manufacturing Practices (cGMP) facility that will purify arGentis' collagen products portfolio. Initially bovine native type 1 collagen (CI) will be purified for use in ARG201, arGentis' treatment for systemic sclerosis (SSc). Pending discussions with the FDA, ARG201 is expected to enter a Phase III clinical trial in 2008. arGentis will also produce various types of highly purified (greater than 98%) collagen used for the research and the...
Source: Biotech Business Week (2007-10-08)
|
